Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis

Next Previous
Trial Profile

A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nebokitug (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SPRING OPEN LABEL EXTENSION
  • Sponsors Chemomab Therapeutics

Most Recent Events

  • 01 Dec 2025 According to a Chemomab Therapeutics media release, data from this trial will be presented on November 10, 2025, at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2025.
  • 20 Nov 2025 According to a Chemomab Therapeutics media release, On November 6, 2025, Chemomab reported that data from the Phase 2 SPRING trial assessing nebokitug for the treatment of PSC at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2025.
  • 30 Jun 2025 According to a Chemomab Therapeutics media release, rececent findings from this Phase 2 SPRING trial suggest that nebokitug may have disease-modifying potential in PSC and support advancement to a Phase 3 registration trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top